Dynamic Glucose Enhanced MRI at Ultra-High Field in Glioblastoma Patients

Paech, D; Köhler, C; Schuenke, P; Zaiss, M; Windschuh, J; Bonekamp, D; Bachert, P; Ladd, M; Wick, W; Bendszus, M; Schlemmer, H-P; Radbruch, A

doi:10.1007/s00062-016-0531-2

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Meeting Abstract

Dynamic Glucose Enhanced MRI at Ultra-High Field in Glioblastoma Patients

MPS-Authors

/persons/resource/persons214560

Zaiss, M
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;
Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

https://link.springer.com/content/pdf/10.1007%2Fs00062-016-0531-2.pdf
(Publisher version)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Paech, D., Köhler, C., Schuenke, P., Zaiss, M., Windschuh, J., Bonekamp, D., et al. (2016). Dynamic Glucose Enhanced MRI at Ultra-High Field in Glioblastoma Patients. Clinical Neuroradiology, 26(Supplement 1): 196, S20.

Cite as: https://hdl.handle.net/21.11116/0000-0003-601A-4

Abstract

Purpose: To investigate if a tumor contrast can be obtained in glioblastoma patients at ultra-high field magnetic resonance imaging (MRI) using simple D-glucose as biodegradable contrast agent.
Patients & Methods: 8 newly diagnosed glioblastoma patients were included in this prospective ethic approved study. Adiabatic chemical exchange sensitive spin-lock (CESL) preparation followed by conventional
MRI readout was realized at a 7 Tesla (7 T) whole-body scanner. 100 ml of 20 % D-glucose were injected manually after 4 minutes baseline measurements yielding the 5 second time-resolved dynamic glucose enhanced (DGE) contrast.
Results: No complication after glucose injection was observed in any patient. In all analyzed patients a DGE contrast was obtained that allowed the identification of the tumor and time-resolved visualization
of intratumoral glucose uptake (Fig. 1). Glucose enhanced signal intensity was significantly increased in glioblastoma tumors compared to contralateral normal appearing white matter (p < 0.001).
Discussion: Our investigations in a homogenous glioblastoma patient
collective showed that simple glucose can be used in ultra-high field DGE imaging as biodegradable contrast agent for the visualization of intracranial tumors generating new insights into tumor metabolism.